Daratumumab for the Treatment of Multiple Myeloma

Front Immunol. 2018 Jun 4:9:1228. doi: 10.3389/fimmu.2018.01228. eCollection 2018.

Authors

Torben Plesner¹, Jakub Krejcik²

Affiliations

¹ Institute of Regional Health Science, University of Southern Denmark, Vejle Hospital, Vejle, Denmark.
² Department of Hematology, Vejle Hospital, Vejle, Denmark.

Abstract

This mini-review will summarize the present state of development of the CD38 antibody daratumumab for the treatment of multiple myeloma.

Keywords: CD38; adenosine; complement; daratumumab; immunomodulation; myeloma; neonatal Fc-receptors; trogocytosis.

Publication types

Review

MeSH terms

Animals
Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal / therapeutic use*
Antibody-Dependent Cell Cytotoxicity
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Clinical Trials as Topic
Cytotoxicity, Immunologic
Drug Evaluation, Preclinical
Humans
Multiple Myeloma / drug therapy*
Multiple Myeloma / immunology
Multiple Myeloma / metabolism
Treatment Outcome

Substances

Antibodies, Monoclonal
Antineoplastic Agents
daratumumab